Comparison of morning versus evening dosing and 24-h post-dose efficacy of travoprost compared with latanoprost in patients with open-angle glaucoma

ABSTRACT

Objective: To compare the IOP-lowering efficacy of a.m.-dosed travoprost and latanoprost at 24-h post-dose.

Research design and methods: Open-angle glaucoma patients not naïve to prostaglandin therapy and currently controlled on p.m.-dosed (2100) latanoprost (n = 21) or travoprost (n = 30) had baseline IOPs measured at 0900. In a randomized, single-masked, crossover design, patients received travoprost (Travatan) or latanoprost (Xalatan) at 0900 for 4 weeks, then were crossed over to receive the second prostaglandin for another 4 weeks. Treatment IOP was measured at 0900 prior to morning dose at both 4 and 8 week visits. Patient dosing preference (a.m./p.m.) was surveyed on exit.

Main outcome measure: Intraocular pressure (IOP).

† Travatan is a registered trade name of Alcon Laboratories, Inc., Fort Worth, TX, USA

‡ Xalatan is a registered trade name of Pfizer, New York, NY, USA

Results: The mean IOP in the first period when all patients were dosed in the evening was assessed 12 h after dosing at 09:00 and it was similar in the two treatment groups (mean ± standard deviation: 17.9 ± 2.7 mmHg for travoprost versus 17.7 ± 2.5 mmHg for latanoprost, p = 0.812). In the a.m.-dosing crossover comparison, the 24-h post-dose IOP was significantly lower ( p < 0.001) on travoprost (16.9 ± 3.1 mmHg) compared to latanoprost (18.6 ± 3.3 mmHg). In the exit survey, 51% of patients preferred a.m.-dosing.

Conclusions: a.m.-dosed travoprost is superior to a.m.-dosed latanoprost by 1.7 mmHg at 24-h post-dose.

Key words: :

• Glaucoma
• Latanoprost
• Medical therapy
• Morning dosing
• Prostaglandin analogue
• Travoprost

Acknowledgements

Declaration of interest: This study was not supported by any public, corporate, or private interest, and the authors declare no editorial assistance in preparing the manuscript.

Notes

* The data in this paper were previously presented at the International Glaucoma Symposium, Athens, Greece, March 28–31, 2007; at the Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, FL, USA, May 6–10, 2007; and at the World Glaucoma Congress, Singapore, July 18–21, 2007

† Travatan is a registered trade name of Alcon Laboratories, Inc., Fort Worth, TX, USA

‡ Xalatan is a registered trade name of Pfizer, New York, NY, USA

† Travatan is a registered trade name of Alcon Laboratories, Inc., Fort Worth, TX, USA

‡ Xalatan is a registered trade name of Pfizer, New York, NY, USA